

# A Double Blind, Randomised, Placebo Controlled Study of Farlutal in the Treatment of Weight Loss in Patients Undergoing Radiotherapy for Head and Neck Cancer

<b>Submission date</b>	<b>Recruitment status</b>	<input type="checkbox"/> Prospectively registered
19/08/2002	No longer recruiting	<input type="checkbox"/> Protocol
<b>Registration date</b>	<b>Overall study status</b>	<input type="checkbox"/> Statistical analysis plan
19/08/2002	Completed	<input type="checkbox"/> Results
<b>Last Edited</b>	<b>Condition category</b>	<input type="checkbox"/> Individual participant data
03/03/2008	Cancer	<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr --

### Contact details

UKCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

### Protocol serial number

MPA8801

## Study information

### Scientific Title

**Study objectives**

Not provided at time of registration

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Not Specified

**Health condition(s) or problem(s) studied**

Head and Neck Cancer

**Interventions**

1. Group A: Oral medroxyprogesterone acetate 500 mg twice daily for a maximum of 12 weeks
2. Group B: Placebo tablets twice daily for a maximum of 12 weeks

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

Not provided at time of registration

**Key secondary outcome(s))**

Not provided at time of registration

**Completion date**

19/08/2005

## Eligibility

**Key inclusion criteria**

1. Aged >18 years
2. Squamous cell carcinoma of the head and neck
3. Not known to have or suspected of having early breast cancer
4. No known hypersensitivity to medroxyprogesterone acetate
5. No medical contraindications to treatment

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Lower age limit**

18 years

**Sex**

Not Specified

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

19/08/2000

**Date of final enrolment**

19/08/2005

## Locations

**Countries of recruitment**

United Kingdom

England

Italy

**Study participating centre**

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

## Sponsor information

**Organisation**

Farmitalia Carlo Erba (Italy)

ROR

## Funder(s)

### Funder type

Not defined

### Funder Name

Not provided at time of registration.

## Results and Publications

### Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration